Dianthus Therapeutics' Claseprubart Shows 75% Response in Interim Phase 3 CIDP Data
DNTH has more than doubled off its 52-week low of $16.635.
Summary
Dianthus Therapeutics announced highly positive interim Phase 3 data for its lead candidate, claseprubart, in chronic inflammatory demyelinating polyneuropathy (CIDP). The CAPTIVATE trial demonstrated a 75% confirmed response rate among the first 40 patients, alongside a favorable safety profile with no serious infections or autoimmune activation. This strong data supports the trial's continuation and is a significant de-risking event for the company's pipeline, moving it closer to potential regulatory approval. This update builds on previous positive clinical updates and the company's strong cash position of approximately $1.2 billion, which extends its runway into 2030. Investors will now look towards the top-line results for Part B of the CAPTIVATE trial, which are anticipated by year-end 2026.
At the time of this announcement, DNTH was trading at $76.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.2B. The 52-week trading range was $16.64 to $96.50. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.